Evidence map›Paper›PMID 40397198›Full record

ArticleNeuromolecular medicine2025

Protective Effect of the LRRK2 Kinase Inhibition in Human Fibroblasts Bearing the Genetic Variant GBA1 K198E: Implications for Parkinson's Disease.

Laura Patricia Perez-Abshana, Miguel Mendivil-Perez, Carlos Velez-Pardo, Marlene Jimenez-Del-Rio

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuromolecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laura Patricia Perez-AbshanaNeuroscience Research Group, Faculty of Medicine, Institute of Medical Research, University of Antioquia, University Research Headquarters, Calle 70 #52-21 and Calle 62#52-59, Building 1, Laboratory 411/412, Medellin, 050010, Colombia.ORCID http://orcid.org/0000-0002-2047-7194
Miguel Mendivil-PerezNeuroscience Research Group, Faculty of Medicine, Institute of Medical Research, University of Antioquia, University Research Headquarters, Calle 70 #52-21 and Calle 62#52-59, Building 1, Laboratory 411/412, Medellin, 050010, Colombia.ORCID http://orcid.org/0000-0002-8824-379X
Carlos Velez-PardoNeuroscience Research Group, Faculty of Medicine, Institute of Medical Research, University of Antioquia, University Research Headquarters, Calle 70 #52-21 and Calle 62#52-59, Building 1, Laboratory 411/412, Medellin, 050010, Colombia.ORCID http://orcid.org/0000-0002-0557-0411
Marlene Jimenez-Del-RioNeuroscience Research Group, Faculty of Medicine, Institute of Medical Research, University of Antioquia, University Research Headquarters, Calle 70 #52-21 and Calle 62#52-59, Building 1, Laboratory 411/412, Medellin, 050010, Colombia. marlene.jimenez@udea.edu.co.ORCID http://orcid.org/0000-0003-3477-2386

Funding

Departamento Administrativo de Ciencia, Tecnología e Innovación (COLCIENCIAS) 1115-844-67799
6 · The paper itself

Abstract

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder for which there are currently no curative therapies. Therefore, the need for innovative treatments for this illness is critical. The glucosylceramidase beta 1 (GBA1) and leucine-rich repeated kinase 2 (LRRK2) genes have been postulated as potential genetically defined drug targets. We report for the first time that the LRRK2 inhibitor PF-06447475 (PF-475) not only restores GCase enzyme activity, but also increases mitochondrial membrane potential, significantly decreases DJ-1 Cys106-SO

Indexed as

FibroblastsGlucosylceramidaseLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Parkinson DiseaseProtein Kinase InhibitorsProtein Serine-Threonine KinasesAutophagyCaspase 3Cells, CulturedHumansIndazolesInositolLysosomesMembrane Potential, MitochondrialPyrimidinesrab GTP-Binding Proteins2,6-dimethyl-4-(6-(5-(1-methylcyclopropoxy)-1H-indazol-3-yl)pyrimidin-4-yl)morpholineCaspase 3GBA protein, humanGlucosylceramidaseIndazolesInositolLeucine-Rich Repeat Serine-Threonine Protein Kinase-2LRRK2 protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesPyrimidinesRab10 protein, humanrab GTP-Binding ProteinsFibroblastsGBALRRK2Parkinson’s diseasePF-06447475RAB10

Identifiers

PMID40397198
PMCPMC12095415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.